Bicycle Therapeutics (BCYC) Stock Forecast, Price Target & Predictions
BCYC Stock Forecast
Bicycle Therapeutics stock forecast is as follows: an average price target of $43.67 (represents a 191.13% upside from BCYC’s last price of $15.00) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
BCYC Price Target
The average price target for Bicycle Therapeutics (BCYC) is $43.67 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $28.00. This represents a potential 191.13% upside from BCYC's last price of $15.00.
BCYC Analyst Ratings
According to 9 Wall Street analysts, Bicycle Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BCYC stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bicycle Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | Jay Olson | Oppenheimer | $48.00 | $25.32 | 89.57% | 220.00% |
| Oct 24, 2024 | Kalpit Patel | B.Riley Financial | $28.00 | $25.32 | 10.58% | 86.67% |
| Sep 16, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $55.00 | $27.02 | 103.55% | 266.67% |
| Oct 07, 2021 | Edward Tenthoff | Piper Sandler | $76.00 | $48.69 | 56.09% | 406.67% |
| Oct 07, 2021 | Anthony Butler | Roth Capital | $65.00 | $48.69 | 33.50% | 333.33% |
The latest Bicycle Therapeutics stock forecast, released on Oct 24, 2024 by Jay Olson from Oppenheimer, set a price target of $48.00, which represents a 89.57% increase from the stock price at the time of the forecast ($25.32), and a 220.00% increase from BCYC last price ($15.00).
Bicycle Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $38.00 | $43.67 |
| Last Closing Price | $15.00 | $15.00 | $15.00 |
| Upside/Downside | -100.00% | 153.33% | 191.13% |
In the current month, the average price target of Bicycle Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bicycle Therapeutics's last price of $15.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Oct 24, 2024 | RBC Capital | Market Outperform | Market Outperform | Hold |
| Oct 24, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Oct 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 24, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | RBC Capital | Buy | Buy | Hold |
| Sep 06, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Sep 05, 2024 | RBC Capital | Outperform | Initialise | |
| Aug 07, 2024 | Oppenheimer | Buy | Buy | Hold |
| Aug 07, 2024 | B. Riley | Neutral | Downgrade | |
| Jun 03, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Feb 21, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 21, 2024 | JMP Securities | Underperform | Underperform | Hold |
| Feb 21, 2024 | Needham | Market Outperform | Market Outperform | Hold |
| Dec 20, 2023 | Needham | Market Outperform | Market Outperform | Hold |
| Dec 20, 2023 | Morgan Stanley | Underperform | Underperform | Hold |
| Sep 12, 2023 | Maxim Group | Buy | Initialise |
Bicycle Therapeutics's last stock rating was published by Leerink Partners on Oct 31, 2024. The company gave BCYC a "Outperform" rating, the same as its previous rate.
Bicycle Therapeutics Financial Forecast
Bicycle Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $5.35M | $11.40M | $4.90M | $3.19M | $3.04M | $4.38M | $3.86M | $3.77M | $4.33M | $1.78M | $1.81M | $3.85M | $3.84M | $1.57M | $1.13M | $5.28M | $614.00K | $1.52M |
| Avg Forecast | $5.82M | $5.72M | $6.67M | $5.87M | $5.30M | $6.82M | $6.13M | $6.06M | $6.98M | $12.94M | $5.78M | $3.88M | $3.55M | $5.70M | $3.69M | $4.46M | $5.52M | $5.75M | $2.31M | $1.81M | $3.66M | $2.73M | $2.36M | $3.50M | $1.48M | $1.32M | $1.03M |
| High Forecast | $10.02M | $9.84M | $11.48M | $10.10M | $10.59M | $6.88M | $6.13M | $6.06M | $15.75M | $13.02M | $9.94M | $6.67M | $6.12M | $5.70M | $3.69M | $4.46M | $5.52M | $5.75M | $2.31M | $1.81M | $3.66M | $2.73M | $2.36M | $3.50M | $1.48M | $1.32M | $1.03M |
| Low Forecast | $3.29M | $3.23M | $3.77M | $3.32M | $2.38M | $6.76M | $6.13M | $6.06M | $2.99M | $12.87M | $3.26M | $2.19M | $2.01M | $5.70M | $3.69M | $4.46M | $5.52M | $5.75M | $2.31M | $1.81M | $3.66M | $2.73M | $2.36M | $3.50M | $1.48M | $1.32M | $1.03M |
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.41% | 1.97% | 1.26% | 0.90% | 0.53% | 1.19% | 0.86% | 0.68% | 0.75% | 0.77% | 1.00% | 1.05% | 1.41% | 0.67% | 0.32% | 3.57% | 0.47% | 1.47% |
Bicycle Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $6.98M, with a low forecast of $2.99M, and a high forecast of $15.75M. BCYC's average Quarter revenue forecast represents a 30.48% increase compared to the company's last Quarter revenue of $5.35M (Sep 23).
Bicycle Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-50.80M | $-41.04M | $-38.87M | $-29.57M | $-26.70M | $-26.39M | $-26.63M | $-17.56M | $-13.93M | $-16.91M | $-15.68M | $-16.72M | $-10.27M | $-11.90M | $-11.13M | $-4.27M | $-9.57M | $-9.85M |
| Avg Forecast | $-5.82M | $-5.72M | $-6.67M | $-5.87M | $-5.30M | $-6.82M | $-6.13M | $-6.06M | $-6.98M | $-12.94M | $-5.78M | $-3.88M | $-3.55M | $-5.70M | $-3.69M | $-16.91M | $-5.52M | $-5.75M | $-2.31M | $-15.24M | $-3.66M | $-2.73M | $-2.36M | $-77.38M | $-1.48M | $-1.32M | $-10.95M |
| High Forecast | $-3.29M | $-3.23M | $-3.77M | $-3.32M | $-2.38M | $-6.76M | $-6.13M | $-6.06M | $-2.99M | $-12.87M | $-3.26M | $-2.19M | $-2.01M | $-5.70M | $-3.69M | $-13.53M | $-5.52M | $-5.75M | $-2.31M | $-12.19M | $-3.66M | $-2.73M | $-2.36M | $-61.90M | $-1.48M | $-1.32M | $-8.76M |
| Low Forecast | $-10.02M | $-9.84M | $-11.48M | $-10.10M | $-10.59M | $-6.88M | $-6.13M | $-6.06M | $-15.75M | $-13.02M | $-9.94M | $-6.67M | $-6.12M | $-5.70M | $-3.69M | $-20.29M | $-5.52M | $-5.75M | $-2.31M | $-18.29M | $-3.66M | $-2.73M | $-2.36M | $-92.85M | $-1.48M | $-1.32M | $-13.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.93% | 7.11% | 10.03% | 8.32% | 4.68% | 7.16% | 1.57% | 3.18% | 2.42% | 7.33% | 1.03% | 4.57% | 3.77% | 5.04% | 0.14% | 2.89% | 7.25% | 0.90% |
undefined analysts predict BCYC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bicycle Therapeutics's previous annual EBITDA (undefined) of $NaN.
Bicycle Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $-49.90M | $-42.60M | $-39.06M | $-29.98M | $-28.35M | $-26.83M | $-27.56M | $-18.04M | $-14.68M | $-17.91M | $-16.19M | $-17.43M | $-10.14M | $-12.12M | $-11.32M | $-4.41M | $-9.48M | $-10.22M |
| Avg Forecast | $-64.71M | $-64.16M | $-58.99M | $-58.87M | $-58.92M | $-54.95M | $-76.42M | $-86.31M | $-85.09M | $-82.84M | $-82.77M | $-74.36M | $-73.05M | $-46.79M | $-44.12M | $-17.43M | $-32.00M | $-31.77M | $-36.97M | $-15.73M | $-24.57M | $-26.91M | $-24.73M | $-78.75M | $-27.24M | $-30.03M | $-11.35M |
| High Forecast | $-28.13M | $-27.89M | $-25.64M | $-25.59M | $-46.59M | $-23.89M | $-33.22M | $-37.52M | $-46.35M | $-16.29M | $-35.98M | $-32.33M | $-31.76M | $-46.79M | $-44.12M | $-13.94M | $-32.00M | $-31.77M | $-36.97M | $-12.59M | $-24.57M | $-26.91M | $-24.73M | $-63.00M | $-27.24M | $-30.03M | $-9.08M |
| Low Forecast | $-125.42M | $-124.35M | $-114.32M | $-114.10M | $-69.19M | $-106.51M | $-148.11M | $-167.27M | $-114.14M | $-130.99M | $-160.42M | $-144.12M | $-141.58M | $-46.79M | $-44.12M | $-20.92M | $-32.00M | $-31.77M | $-36.97M | $-18.88M | $-24.57M | $-26.91M | $-24.73M | $-94.50M | $-27.24M | $-30.03M | $-13.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.60% | 0.51% | 0.53% | 0.41% | 0.61% | 0.61% | 1.58% | 0.56% | 0.46% | 0.48% | 1.03% | 0.71% | 0.38% | 0.49% | 0.14% | 0.16% | 0.32% | 0.90% |
Bicycle Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCYC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Bicycle Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $16.28M | $15.18M | $14.49M | $10.68M | $10.25M | $11.82M | $16.85M | $8.72M | $8.27M | $7.35M | $8.14M | $10.85M | $7.15M | $6.20M | $5.00M | $3.40M | $4.79M | $2.97M |
| Avg Forecast | $14.29M | $14.04M | $16.37M | $14.41M | $13.02M | $16.75M | $15.05M | $14.89M | $17.15M | $31.78M | $14.18M | $9.52M | $8.72M | $14.01M | $9.06M | $10.96M | $13.57M | $14.12M | $5.67M | $4.45M | $8.98M | $6.69M | $5.80M | $8.61M | $3.63M | $3.24M | $2.54M |
| High Forecast | $24.61M | $24.17M | $28.19M | $24.80M | $26.00M | $16.90M | $15.05M | $14.89M | $38.69M | $31.97M | $24.42M | $16.39M | $15.02M | $14.01M | $9.06M | $10.96M | $13.57M | $14.12M | $5.67M | $4.45M | $8.98M | $6.69M | $5.80M | $8.61M | $3.63M | $3.24M | $2.54M |
| Low Forecast | $8.08M | $7.93M | $9.25M | $8.14M | $5.85M | $16.59M | $15.05M | $14.89M | $7.34M | $31.60M | $8.02M | $5.38M | $4.93M | $14.01M | $9.06M | $10.96M | $13.57M | $14.12M | $5.67M | $4.45M | $8.98M | $6.69M | $5.80M | $8.61M | $3.63M | $3.24M | $2.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.51% | 1.07% | 1.52% | 1.22% | 0.73% | 1.31% | 1.54% | 0.64% | 0.59% | 1.30% | 1.83% | 1.21% | 1.07% | 1.07% | 0.58% | 0.93% | 1.48% | 1.17% |
Bicycle Therapeutics's average Quarter SG&A projection for Dec 23 is $17.15M, based on 6 Wall Street analysts, with a range of $7.34M to $38.69M. The forecast indicates a 5.34% rise compared to BCYC last annual SG&A of $16.28M (Sep 23).
Bicycle Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 9 | 4 | 3 | 3 | 6 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-1.41 | $-1.30 | $-1.01 | $-0.96 | $-0.90 | $-0.93 | $-0.63 | $-0.59 | $-0.74 | $-0.73 | $-0.83 | $-0.52 | $-0.67 | $-0.63 | $-0.25 | $-0.53 | $-1.40 |
| Avg Forecast | $-0.94 | $-0.93 | $-0.85 | $-0.85 | $-0.85 | $-0.80 | $-1.11 | $-1.25 | $-1.23 | $-1.20 | $-1.20 | $-1.08 | $-1.06 | $-0.90 | $-0.85 | $-0.68 | $-0.62 | $-0.61 | $-0.71 | $-0.71 | $-0.47 | $-0.52 | $-0.48 | $-0.37 | $-0.52 | $-0.58 | $-0.46 |
| High Forecast | $-0.41 | $-0.40 | $-0.37 | $-0.37 | $-0.68 | $-0.35 | $-0.48 | $-0.54 | $-0.67 | $-0.24 | $-0.52 | $-0.47 | $-0.46 | $-0.90 | $-0.85 | $-0.68 | $-0.62 | $-0.61 | $-0.71 | $-0.71 | $-0.47 | $-0.52 | $-0.48 | $-0.37 | $-0.52 | $-0.58 | $-0.46 |
| Low Forecast | $-1.82 | $-1.80 | $-1.66 | $-1.65 | $-1.00 | $-1.54 | $-2.15 | $-2.42 | $-1.65 | $-1.90 | $-2.33 | $-2.09 | $-2.05 | $-0.90 | $-0.85 | $-0.68 | $-0.62 | $-0.61 | $-0.71 | $-0.71 | $-0.47 | $-0.52 | $-0.48 | $-0.37 | $-0.52 | $-0.58 | $-0.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 1.18% | 1.21% | 0.95% | 1.07% | 1.06% | 1.37% | 1.02% | 0.97% | 1.04% | 1.03% | 1.76% | 1.00% | 1.41% | 1.71% | 0.48% | 0.92% | 3.08% |
According to undefined Wall Street analysts, Bicycle Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCYC previous annual EPS of $NaN (undefined).
Bicycle Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| ANAB | AnaptysBio | $15.99 | $49.83 | 211.63% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| BCYC | Bicycle Therapeutics | $15.14 | $43.67 | 188.44% | Buy |
| IGMS | IGM Biosciences | $7.48 | $18.67 | 149.60% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ORIC | ORIC Pharmaceuticals | $8.25 | $20.00 | 142.42% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| IDYA | IDEAYA Biosciences | $26.33 | $53.33 | 102.54% | Buy |
| MRUS | Merus | $44.90 | $81.25 | 80.96% | Buy |
| MGTX | MeiraGTx | $6.40 | $9.00 | 40.63% | Buy |